PYXS News and Press, Pyxis Oncology Inc. From 09/19/23

2023-09-19 13:37:04 ET More on Pyxis Oncology Seeking Alpha’s Quant Rating on Pyxis Oncology Historical earnings data for Pyxis Oncology Financial information for Pyxis Oncology Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed...

2023-09-07 08:09:09 ET Summary Pyxis Oncology completed an acquisition of Apexigen, adding to its pipeline and bringing in a drug called sotigalimab. Pyxis Oncology's pipeline includes PYX-106 and PYX-201, with preliminary data expected in late 2023 and early 2024, respectively. ...

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences. On September 6, 2023, me...

Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Ca...

2023-08-11 10:25:26 ET Pyxis Oncology press release ( NASDAQ: PYXS ): Q2 GAAP EPS of -$0.41. As of June 30, 2023, Pyxis Oncology had cash and cash equivalents (including restricted cash) and short-term investments of $144.1 million For further details see: Pyxis ...

Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen transaction anticipated to close later in August Strong balance sheet with $144 mill...

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will present a compa...

2023-06-15 08:20:40 ET Summary An anti-EDB ADC, known as PYX-201 is being explored in a phase 1 study treating patients with breast, head and neck, lung and thyroid cancer. An anti-Siglec-15 drug, known as PYX-106, is being advanced in a phase 1 study treating patients with Bladde...

2023-06-12 02:59:50 ET Summary Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product candidates, PYX-201 and PYX-106, are currently in ...

First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate Preliminary data from both trials on track for late-2023/early-2024 timeframe ...